Fig. 3.

BCR-ABL1 clonal evolution in ALL patients predicted disease progression and relapse. (a) 1R1G2F was sensitive single clone at disease onset, which disappeared after treatment, and it was still the primary clone (1R1G2F) during relapse. (b) 1R1G2F was sensitive single clone at disease onset, which disappeared after treatment, whereas new single clone (1R1G4F) was observed during relapse. (c) 1R1G2F was sensitive single clone at disease onset, whereas new and primary clones (1R1G2F and 1R1G3F) simultaneously occurred during relapse. (d) 1R1G2F, 1R1G3F and 1R1G4F presented different subclones during disease onset, some subclones (1R1G4F and 1R1G3F) were sensitive, whereas minor subclones (1R1G2F) were resistant. (d) 1R1G2F and 1R1G3F presented two different subclones at disease onset. Minor subclones (1R1G2F) were sensitive, whereas the preponderant subclones (1R1G3F) were resistant